Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Analysis 2025-2030: Growth Drivers, Challenges, And Opportunities

The Vasomotor Menopausal Symptoms (VMS) Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

How Big Is the Vasomotor Menopausal Symptoms (VMS) Treatment Market Size Expected to Be by 2034?
In recent times, the market size for the treatment of vasomotor menopausal symptoms (VMS) has shown notable growth. It is projected to expand from a value of $17.86 billion in 2024 to $19.19 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.5%. Factors such as hormone replacement therapy (hrt), increased awareness about menopause, developments in the pharmaceutical sector, and consumer demand are considered to be the key drivers behind this growth during the historic period.

The market size for treating vasomotor menopausal symptoms (VMS) is projected to experience robust expansion going forward, with a predicted value of $24.81 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period is a result factors such as personalized medicine, advancements in non-hormonal treatments, nutritional and dietary strategies, telemedicine, and digital health innovations. Key trends expected during this period encompass natural and alternative treatments, botanical and herbal solutions, support groups for menopause, and cognitive behavioral therapy (cbt).

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051

What Are the Emerging Segments Within the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented -

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants
2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

What Long-Term Drivers Are Shaping Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends?
The growth of the vasomotor menopausal symptom treatment market is projected to accelerate due to an increasing menopause population. Menopause is a biological phase marking the conclusion of a woman's childbearing years typically experienced between ages 45 and 55, with the median age being 51. The global surge in menopausal women needing relief from hot flashes and vaginal dryness serves as a primary catalyst in the expansion of the vasomotor menopausal symptoms (VMS) treatment market. The Cuyuna Regional Medical Center, based in the US, for instance, estimated in November 2022 that women living longer will lead to a staggering 1.1 billion women becoming menopausal by 2025. Furthermore, the menopausal population is projected to grow annually by 1.6% through 2060. As a result, the swelling menopause demographic is fueling the vasomotor menopausal symptom's treatment market's robust trajectory. Growth Driver for the Vasomotor Menopausal Symptoms (VMS) Treatment Market: Enhancing Women's Health through Government Initiatives

Who Are the Top Competitors in Key Vasomotor Menopausal Symptoms (VMS) Treatment Market Segments?
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

What Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends Are Gaining Traction Across Different Segments?
Major corporations present in the vasomotor menopausal symptoms treatment market, such as Astellas Pharma Inc, are innovating new products like Veozah to offer fresh therapeutic solutions and fulfill the unfulfilled medical requirements of patients. The authorization of new menopausal drugs brings about enhanced efficiency and safety as against the existing treatments. For example, the Japan-based pharmaceutical firm, Astellas Pharma Inc, got clearance from the Food and Drug Administration (FDA), an American federal agency, for Veozah (fezolinetant) 45 mg once daily in May 2023, to treat vasomotor symptoms (VMS) of menopause, varying from mild to severe. Veozah is a groundbreaking nonhormonal neurokinin 3 (NK3) receptor antagonist authorized for menopausal-related VMS. It is a hormone-free choice that obstructs a pathway within the brain managing these symptoms. For women experiencing these symptoms, especially those who cannot or opt not to use hormone therapy, it offers an alternative treatment solution. The FDA's green light to Veozah indicates its prospective capabilities as a novel drug for managing menopausal symptoms.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

Which Regions Are Becoming Hubs for Vasomotor Menopausal Symptoms (VMS) Treatment Market Innovation?
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
2. What is the CAGR expected in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
3. What Are the Key Innovations Transforming the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?
4. Which Region Is Leading the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.